Literature DB >> 28549228

Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?

Sebastiano Buti1, Melissa Bersanelli1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28549228     DOI： 10.1200/JCO.2016.71.6506

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.

Authors:  Roberto Iacovelli; Chiara Ciccarese; Giuseppe Fornarini; Francesco Massari; Davide Bimbatti; Claudia Mosillo; Sara Elena Rebuzzi; Vincenzo Di Nunno; Massimiliano Grassi; Emanuela Fantinel; Andrea Ardizzoni; Giampaolo Tortora
Journal:  Br J Clin Pharmacol       Date:  2019-03-31       Impact factor: 4.335

2.  First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.

Authors:  Yingjie Su; Jie Fu; Jiangyang Du; Bin Wu
Journal:  Ther Adv Med Oncol       Date:  2020-08-17       Impact factor: 8.168

3.  First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.

Authors:  XiaoMin Wan; YuCong Zhang; ChongQing Tan; XiaoHui Zeng; LiuBao Peng
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777

4.  Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.

Authors:  Junpeng Wang; Xin Li; Xiaoqiang Wu; Zhiwei Wang; Chan Zhang; Guanghui Cao; Xiaofan Zhang; Feng Peng; Tianzhong Yan
Journal:  EBioMedicine       Date:  2019-08-19       Impact factor: 8.143

Review 5.  Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential.

Authors:  Melissa Bersanelli; Sebastiano Buti
Journal:  Ther Adv Med Oncol       Date:  2017-08-02       Impact factor: 8.168

Review 6.  Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date.

Authors:  Melissa Bersanelli; Francesco Leonardi; Sebastiano Buti
Journal:  Cancer Manag Res       Date:  2018-09-21       Impact factor: 3.989

7.  Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.

Authors:  Matteo Santoni; Daniel Y Heng; Sergio Bracarda; Giuseppe Procopio; Michele Milella; Camillo Porta; Marc R Matrana; Giacomo Cartenì; Simon J Crabb; Ugo De Giorgi; Umberto Basso; Cristina Masini; Fabio Calabrò; Maria Giuseppa Vitale; Daniele Santini; Francesco Massari; Luca Galli; Giuseppe Fornarini; Riccardo Ricotta; Sebastiano Buti; Paolo Zucali; Orazio Caffo; Franco Morelli; Francesco Carrozza; Angelo Martignetti; Alain Gelibter; Roberto Iacovelli; Alessandra Mosca; Francesco Atzori; Nuno Vau; Lorena Incorvaia; Cinzia Ortega; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Vittorio Paolucci; Jeffrey Graham; Erin Pierce; Sarah Scagliarini; Pierangela Sepe; Elena Verzoni; Sara Merler; Mimma Rizzo; Giulia Sorgentoni; Alessandro Conti; Francesco Piva; Alessia Cimadamore; Rodolfo Montironi; Nicola Battelli
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.